ALDX Aldeyra Therapeutics Inc
Price (delayed)
$5.475
Market cap
$326.9M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.94
Enterprise value
$287.68M
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's
Highlights
Aldeyra Therapeutics's debt has decreased by 2.3% YoY
The net income has contracted by 49% YoY and by 25% from the previous quarter
The company's EPS fell by 47% YoY and by 25% QoQ
Key stats
What are the main financial stats of ALDX
Market
Valuations
Earnings
Shares outstanding
59.71M
Market cap
$326.9M
Enterprise value
$287.68M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.59
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$60.12M
Net income
-$55.85M
EBIT
-$53.93M
EBITDA
-$53.68M
Free cash flow
-$43.21M
Per share
Balance sheet
Liquidity
EPS
-$0.94
EPS diluted
-$0.94
Free cash flow per share
-$0.73
Book value per share
$1.19
Revenue per share
$0
TBVPS
$1.76
Total assets
$104.61M
Total liabilities
$33.6M
Debt
$15.3M
Equity
$71M
Working capital
$85.47M
Debt to equity
0.22
Current ratio
5.59
Quick ratio
5.44
Net debt/EBITDA
0.73
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-45.7%
Return on equity
-60.7%
Return on invested capital
-126.7%
Return on capital employed
-62.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALDX stock price
How has the Aldeyra Therapeutics stock price performed over time
Intraday
-4.78%
1 week
-18.04%
1 month
7.14%
1 year
67.43%
YTD
9.72%
QTD
-4.78%
Financial performance
How have Aldeyra Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$60.12M
Net income
-$55.85M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 49% YoY and by 25% from the previous quarter
Aldeyra Therapeutics's operating income has decreased by 40% YoY and by 21% QoQ
Growth
What is Aldeyra Therapeutics's growth rate over time
Valuation
What is Aldeyra Therapeutics stock price valuation
P/E
N/A
P/B
4.59
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 47% YoY and by 25% QoQ
ALDX's price to book (P/B) is 72% more than its 5-year quarterly average of 2.8 and 66% more than its last 4 quarters average of 2.9
ALDX's equity is down by 41% year-on-year and by 17% since the previous quarter
Efficiency
How efficient is Aldeyra Therapeutics business performance
The ROE has plunged by 106% YoY and by 41% from the previous quarter
The return on invested capital has surged by 95% year-on-year and by 9% since the previous quarter
The return on assets has dropped by 89% year-on-year and by 36% since the previous quarter
Dividends
What is ALDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALDX.
Financial health
How did Aldeyra Therapeutics financials performed over time
The total assets has declined by 29% year-on-year and by 11% since the previous quarter
ALDX's total liabilities is up by 18% YoY and by 4.3% QoQ
Aldeyra Therapeutics's debt is 78% lower than its equity
The company's debt to equity has surged by 69% YoY and by 22% QoQ
ALDX's equity is down by 41% year-on-year and by 17% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.